Список проголосовавших за комментарий " Ritter Pharmaceuticals downgrade details — to Hold at Maxim Group following last night's data release (1.46 -0.49)Maxim Group downgrades RTTR to Hold from Buy. Firm admits the data release is confusing as the company states: «The primary endpoint met statistical significance, in which 40% of the pooled dosing group and 26% of the placebo group responded (p=0.0159).» Firm feels this is unusual at best. The study missed statistical significance. You can't just exclude a fourth of patients because there are irregularities at one site. A high placebo rate seemed to hurt the trial results. On the other hand firm recognizes this is a phase II study, not a pivotal trial. Can Ritter raise the capital to move this to a pivotal trial and with a delta of just 14%, should they? Next Step: End of Phase II meeting (fall 2017)."